Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.

Hendricksen, Kees; Aziz, Atiqullah; Bes, Perrine; Chun, Felix K-H; Dobruch, Jakub; Kluth, Luis A; Gontero, Paolo; Necchi, Andrea; Noon, Aidan P; van Rhijn, Bas W G; Rink, Michael; Roghmann, Florian; Rouprêt, Morgan; Seiler, Roland; Shariat, Shahrokh F; Qvick, Brian; Babjuk, Marek; Xylinas, Evanguelos (2019). Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey. European urology focus, 5(4), pp. 681-688. Elsevier 10.1016/j.euf.2017.09.002

Full text not available from this repository. (Request a copy)

BACKGROUND

The European Association of Urology (EAU) non-muscle-invasive bladder cancer (NMIBC) guidelines are meant to help minimise morbidity and improve the care of patients with NMIBC. However, there may be underuse of guideline-recommended care in this potentially curable cohort.

OBJECTIVE

To assess European physicians' current practice in the management of NMIBC and evaluate its concordance with the EAU 2013 guidelines.

DESIGN, SETTING, AND PARTICIPANTS

Initial 45-min telephone interviews were conducted with 20 urologists to develop a 26-item questionnaire for a 30-min online quantitative interview. A total of 498 physicians with predefined experience in treatment of NMIBC patients, from nine European countries, completed the online interviews.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS

Descriptive statistics of absolute numbers and percentages of the use of diagnostic tools, risk group stratification, treatment options chosen, and follow-up regimens were used.

RESULTS AND LIMITATIONS

Guidelines are used by ≥87% of physicians, with the EAU guidelines being the most used ones (71-100%). Cystoscopy (60-97%) and ultrasonography (42-95%) are the most used diagnostic techniques. Using EAU risk classification, 40-69% and 88-100% of physicians correctly identify all the prognostic factors for low- and high-risk tumours, respectively. Re-transurethral resection of the bladder tumour (re-TURB) is performed in 25-75% of low-risk and 55-98% of high-risk patients. Between 21% and 88% of patients received a single instillation of chemotherapy within 24h after TURB. Adjuvant intravesical treatment is not given to 6-62%, 2-33%, and 1-20% of the patients with low-, intermediate-, and high-risk NMIBC, respectively. Patients with low-risk NMIBC are likely to be overmonitored and those with high-risk NMIBC undermonitored. Our study is limited by the possible recall bias of the selected physicians.

CONCLUSIONS

Although most European physicians claim to apply the EAU guidelines, adherence to them is low in daily practice.

PATIENT SUMMARY

Our survey among European physicians investigated discrepancies between guidelines and daily practice in the management of non-muscle-invasive bladder cancer (NMIBC). We conclude that the use of the recommended diagnostic tools, risk-stratification of NMIBC, and performance of re-TURB have been adopted, but adjuvant intravesical treatment and follow-up are not uniformly applied.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology
UniBE Contributor:	Seiler-Blarer, Roland
Subjects:	600 Technology > 610 Medicine & health
ISSN:	2405-4569
Publisher:	Elsevier
Language:	English
Submitter:	Laetitia Hayoz
Date Deposited:	30 Jan 2018 14:31
Last Modified:	02 Mar 2023 23:30
Publisher DOI:	10.1016/j.euf.2017.09.002
PubMed ID:	29074050
Uncontrolled Keywords:	Clinical practice Non–muscle-invasive bladder cancer Physician Survey Treatment guidelines Urologist
URI:	https://boris.unibe.ch/id/eprint/108757